|
1.
|
|
7 p, 637.7 KB |
Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker
/
Rouprêt, Morgan (Sorbonne Université GRC 5 Predictive Onco-Uro. Urology Department. AP-HP. Hôpital Pitié-Salpêtrière) ;
Gontero, Paolo (Ospedale Molinette) ;
McCracken, Stuart R.C. (Sunderland Royal Hospital) ;
Dudderidge, Tim (University Hospital Southampton) ;
Stockley, Jacqueline (Arquer Diagnostics) ;
Kennedy, Ashleigh (Arquer Diagnostics) ;
Rodríguez Faba, Óscar (Institut d'Investigació Biomèdica Sant Pau) ;
Sieverink, Caroline (Radboud University Medical Centre) ;
Vanié, Felicien (Hôpital Pitié-Salpêtrière) ;
Allasia, Marco (Ospedale Molinette) ;
Witjes, J.Alfred (Radboud University Medical Centre) ;
Colombel, Marc (Hôpital Edouard Herriot) ;
Longo, Fabrizio (Università Policlinico Milano) ;
Montanari, Emanuele (Università Policlinico Milano) ;
Palou, Joan (Ospedale Molinette) ;
Sylvester, Richard J. (European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel) ;
Universitat Autònoma de Barcelona
Non-muscle-invasive bladder cancer (NMIBC) is one of the most expensive cancers owing to frequent follow-up cystoscopies for detection of recurrence. Objective: To assess if the noninvasive ADXBLADDER urine test could permit a less intensive surveillance schedule for patients with low-grade (LG) pTa tumor without carcinoma in situ (CIS) at the previous diagnosis. [...]
2022 -  10.1016/j.euf.2022.02.006
European Urology Focus, Vol. 8 Núm. 6 (november 2022) , p. 1643-1649
|
|
|
2.
|
|
16 p, 3.2 MB |
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer : A Systematic Review and Network Meta-analysis
/
Laukhtina, Ekaterina (Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia) ;
Shim, Sung Ryul (Department of Preventive Medicine. Korea University College of Medicine) ;
Mori, Keiichiro (Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan) ;
D'Andrea, David (Department of Urology. Comprehensive Cancer Center. Medical University of Vienna) ;
Soria, Francesco (Division of Urology. Department of Surgical Sciences. San Giovanni Battista Hospital. University of Studies of Torino) ;
Rajwa, Pawel (Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland) ;
Mostafaei, Hadi (Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran) ;
Compérat, Eva (Department of Pathology. Comprehensive Cancer Center. Medical University of Vienna) ;
Cimadamore, Alessia (Section of Pathological Anatomy. Marche Polytechnic University. School of Medicine. United Hospitals) ;
Moschini, Marco (Department of Urology and Division of Experimental Oncology. Urological Research Institute. Vita-Salute San Raffaele) ;
Teoh, Jeremy Yuen-Chun (S.H. Ho Urology Centre. Department of Surgery. Chinese University of Hong Kong) ;
Enikeev, Dmitry (Institute for Urology and Reproductive Health. Sechenov University) ;
Xylinas, Evanguelos (Department of Urology. Bichat-Claude Bernard Hospital. Assistance-Publique-Hôpitaux de Paris. Université de Paris) ;
Lotan, Yair (Department of Urology. University of Texas Southwestern. TX) ;
Palou, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Gontero, Paolo (Division of Urology. Department of Surgical Sciences. San Giovanni Battista Hospital. University of Studies of Torino) ;
Babjuk, Marko (Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic) ;
Witjes, Johannes Alfred M. (Department of Urology. Radboud University) ;
Kamat, Ashish Madhav (Department of Urology. M.D. Anderson Cancer Center. University of Texas. TX) ;
Roupret, Morgan (Urology. Ap-Hp. Hôpital Pitié-Salpêtrière. Sorbonne Université) ;
Shariat, Shahrokh F (Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan) ;
Pradere, Benjamin (Department of Urology. Comprehensive Cancer Center. Medical University of Vienna) ;
Universitat Autònoma de Barcelona
CONTEXT: During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commercially available. However, none of these is recommended by international guidelines so far. [...]
2021 - 10.1016/j.euo.2021.10.003
European urology oncology, Vol. 4 Núm. 6 (january 2021) , p. 927-942
|
|
|
3.
|
|
7 p, 231.0 KB |
Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer : a blinded prospective multicentric study
/
Gontero, P. (Department of Urology. Ospedale Molinette) ;
Montanari, E. (Department of Urology. Universita' Policlinico Milano) ;
Roupret, M. (Urology Department. GRC n°5. ONCOTYPE-URO. AP-HP. Hôpital Pitié-Salpêtrière. Sorbonne Université) ;
Longo, F. (Department of Urology. Universita' Policlinico Milano) ;
Stockley, Jacqueline (Arquer Diagnostics. R&D) ;
Kennedy, A. (Arquer Diagnostics. R&D) ;
Rodríguez Faba, Óscar (Institut d'Investigació Biomèdica Sant Pau) ;
McCracken, S.R.C. (Sunderland Royal Hospital) ;
Dudderidge, T. (University Hospital Southampton) ;
Sieverink, C. (Radboud University Medical Centre. Department of Urology) ;
Vanié, F. (Urology Department. GRC n°5. ONCOTYPE-URO. AP-HP. Hôpital Pitié-Salpêtrière. Sorbonne Université) ;
Allasia, M. (Department of Urology. Ospedale Molinette) ;
Witjes, J.A. (Radboud University Medical Centre. Department of Urology) ;
Sylvester, R. (EAU Non-muscle-Invasive Guidelines Panel. EAU Guidelines Office) ;
Colombel, M. (Department of Urology. Hôpital Edouard Herriot) ;
Palou, Juan (Institut d'Investigació Biomèdica Sant Pau)
Objective: To compare directly the performance of the ADXBLADDER test with that of cytology in the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences. Background: ADXBLADDER is a urine test based on the detection of MCM5, a DNA licensing factor expressed in all cells capable of dividing. [...]
2021 - 10.1111/bju.15194
BJU International, Vol. 127 Núm. 2 (february 2021) , p. 198-204
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
